Pancytopenia due to pyrimethamine triggered by transplant-associated microangiopathy after allogeneic bone marrow transplantation

Takehiko Mori, Jun Kato, Shinichiro Okamoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Toxoplasmosis is one of the life-threatening infections that can occur after hematopoietic stem cell transplantation (HSCT) and also solid organ transplantation. The standard treatment for toxoplasmosis is combination therapy with pyrimethamine and sulfadiazine, both of which inhibit folate metabolism. Therefore, therapy with these agents could result in marrow toxicity including megaloblastic anemia or pancytopenia, which is reversible or preventable with folate supplementation. Transplant-associated microangiopathy (TAM) is another situation where folate is required to compensate for increased erythropoiesis due to hemolysis after allogeneic HSCT. Here, we report a case of severe marrow toxicity manifesting as pancytopenia due to low-dose pyrimethamine, which was triggered by TAM after HSCT.

Original languageEnglish
Pages (from-to)866-867
Number of pages2
JournalJournal of Infection and Chemotherapy
Volume17
Issue number6
DOIs
Publication statusPublished - 2011 Dec

Keywords

  • Folate
  • Hematopoietic stem cell transplantation
  • Pancytopenia
  • Pyrimethamine
  • Transplant-associated microangiopathy

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pancytopenia due to pyrimethamine triggered by transplant-associated microangiopathy after allogeneic bone marrow transplantation'. Together they form a unique fingerprint.

  • Cite this